JO
DNLI icon

John Overdeck’s Denali Therapeutics DNLI Stock Holding History

John Overdeck’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-430,177
Closed -$7.1M – 4656
2025
Q4 		$7.1M Buy
430,177
+163,885
+62% +$2.77M 0.01% 1392
2025
Q3 		$3.87M Buy
266,292
+246,992
+1,280% +$3.55M 0.01% 1656
2025
Q2 		$270K Sell
19,300
-83,103
-81% -$1.17M ﹤0.01% 2828
2025
Q1 		$1.39M Sell
102,403
-77,481
-43% -$1.48M ﹤0.01% 1976
2024
Q4 		$3.67M Buy
179,884
+80,417
+81% +$2.06M 0.01% 1295
2024
Q3 		$2.9M Buy
99,467
+4,600
+5% +$114K 0.01% 1437
2024
Q2 		$2.2M Sell
94,867
-96,638
-50% -$1.86M 0.01% 1492
2024
Q1 		$3.93M Buy
191,505
+163,129
+575% +$3.07M 0.01% 1102
2023
Q4 		$609K Buy
+28,376
New +$562K ﹤0.01% 2356
2023
Q3 		– Sell
-34,400
Closed -$1.02M – 3005
2023
Q2 		$1.02M Sell
34,400
-41,341
-55% -$1.16M ﹤0.01% 1935
2023
Q1 		$1.75M Buy
75,741
+1,306
+2% +$35.9K 0.01% 1470
2022
Q4 		$2.07M Sell
74,435
-186,735
-71% -$5.56M 0.01% 1307
2022
Q3 		$8.02M Buy
261,170
+196,846
+306% +$6.4M 0.03% 569
2022
Q2 		$1.89M Buy
64,324
+34,323
+114% +$899K 0.01% 1236
2022
Q1 		$965K Buy
30,001
+21,425
+250% +$737K ﹤0.01% 1715
2021
Q4 		$382K Sell
8,576
-105,095
-92% -$4.98M ﹤0.01% 3477
2021
Q3 		$5.74M Sell
113,671
-105,744
-48% -$5.96M 0.01% 1135
2021
Q2 		$17.2M Sell
219,415
-277,288
-56% -$17.2M 0.04% 549
2021
Q1 		$28.4M Buy
496,703
+235,633
+90% +$15.8M 0.07% 316
2020
Q4 		$21.9M Buy
261,070
+70,025
+37% +$4.23M 0.06% 333
2020
Q3 		$6.84M Buy
191,045
+65,507
+52% +$1.97M 0.02% 659
2020
Q2 		$3.04M Buy
+125,538
New +$2.95M 0.02% 898

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

John Overdeck's DNLI Position: Q1 2026 in Review

John Overdeck sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 430,177 shares — an estimated $7.1M sold.

John Overdeck first reported a position in DNLI in Q2 2020 and held it in 22 quarters. The position peaked at $28.4M in Q1 2021. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • John Overdeck reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
  • John Overdeck sold 430,177 Denali Therapeutics shares in Q1 2026, an estimated $7.1M.
  • John Overdeck first reported a position in Denali Therapeutics in Q2 2020 and held it in 22 quarters.
  • John Overdeck's Denali Therapeutics position peaked at $28.4M in Q1 2021.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.